HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study.

AbstractBACKGROUND:
Periprocedural anticoagulation management with uninterrupted warfarin and a "therapeutic" international normalized ratio is the best approach for reducing both thromboembolic and bleeding complications in the setting of catheter ablation for atrial fibrillation (AF).
OBJECTIVE:
The purpose of this study was to evaluate the safety and feasibility of uninterrupted apixaban in this setting.
METHODS:
This was a prospective multicenter registry of AF patients undergoing radiofrequency catheter ablation at 4 institutions in United States and Europe with uninterrupted apixaban. These patients were compared with an equal number of patients, matched for age, gender, and type of AF, undergoing AF ablation on uninterrupted warfarin. The apixaban group was comprised of consecutive patients who had taken their last dose of apixaban the morning of the procedure. A subset of 29 patients in the apixaban group underwent diffusion magnetic resonance imaging (dMRI) to detect silent cerebral ischemia.
RESULTS:
A total of 400 patients (200 patients in each group) were included in the study. The average age was 65.9 ± 9.9 years, 286 (71.5%) were male, and 334 (83.5%) had nonparoxysmal AF. There were no statistical differences with regard to major complications (1% vs 0.5%, P = 1), minor complications (3.5% vs 2.5%, P = .56), or total bleeding complications (4.5% vs 3%, P = .43) between the apixaban and warfarin groups. There were no symptomatic thromboembolic complications. All dMRIs were negative for "new" silent cerebral ischemia in the apixaban group.
CONCLUSION:
Uninterrupted apixaban administration in patients undergoing AF ablation seems to be feasible and effective in preventing clinical and silent thromboembolic events without increasing the risk of major bleeding.
AuthorsLuigi Di Biase, Dhanujaya Lakkireddy, Chintan Trivedi, Thomas Deneke, Martin Martinek, Sanghamitra Mohanty, Prasant Mohanty, Sameer Prakash, Rong Bai, Madhu Reddy, Carola Gianni, Rodney Horton, Shane Bailey, Elisabeth Sigmund, Michael Derndorfer, Anja Schade, Patrick Mueller, Atilla Szoelloes, Javier Sanchez, Amin Al-Ahmad, Patrick Hranitzky, G Joseph Gallinghouse, Richard H Hongo, Salwa Beheiry, Helmut Pürerfellner, J David Burkhardt, Andrea Natale
JournalHeart rhythm (Heart Rhythm) Vol. 12 Issue 6 Pg. 1162-8 (Jun 2015) ISSN: 1556-3871 [Electronic] United States
PMID25728754 (Publication Type: Journal Article, Multicenter Study)
CopyrightCopyright © 2015 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Anticoagulants
  • Factor Xa Inhibitors
  • Pyrazoles
  • Pyridones
  • apixaban
  • Warfarin
Topics
  • Aged
  • Anticoagulants (administration & dosage)
  • Atrial Fibrillation (surgery)
  • Catheter Ablation (adverse effects)
  • Diffusion Magnetic Resonance Imaging
  • Factor Xa Inhibitors (administration & dosage)
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Postoperative Hemorrhage (prevention & control)
  • Prospective Studies
  • Pyrazoles (administration & dosage)
  • Pyridones (administration & dosage)
  • Safety
  • Warfarin (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: